论文部分内容阅读
目的:评价乌司他丁对重症脓毒症患者的临床疗效及对炎性因子的影响。方法:选取2013年3月—2014年3月间诊治的重症脓毒症患者76例,将其分为对照组与观察组,各组38例;对照组患者接受常规治疗,观察组患者接受乌司他丁治疗;比较两组患者治疗前后的临床疗效以及炎症介质肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)和白介素-1β(IL-1β)水平值。结果:对照组患者治疗后的总有效率为84.21%略低于观察组为89.47%(P>0.05);治疗前后,两组患者TNF-α、IL-6、IL-1β,经比较其差异有统计学意义(P<0.05);治疗后,上述各观察指标组间经比较其差异有统计学意义(P<0.05)。结论:乌司他丁用于重症脓毒症患者的临床疗效较显著,优于常规治疗。
Objective: To evaluate the clinical efficacy of ulinastatin in patients with severe sepsis and the impact on inflammatory cytokines. Methods: Seventy-six patients with severe sepsis who were diagnosed and treated between March 2013 and March 2014 were divided into control group and observation group, with 38 cases in each group. Patients in control group received routine treatment and patients in observation group received Stinging treatment was performed. The clinical efficacy and the levels of TNF-α, IL-6 and IL-1βin inflammatory mediators before and after treatment were compared between the two groups. Results: The total effective rate of the control group was 84.21%, which was slightly lower than that of the observation group (89.47%) (P> 0.05). Before and after treatment, the difference of TNF-α, IL-6 and IL- (P <0.05). After treatment, the differences among the above observation groups were statistically significant (P <0.05). Conclusion: The clinical efficacy of ulinastatin in patients with severe sepsis is more significant than conventional treatment.